8EM.F · Editas Medicine, Inc

-

Please sign in to comment on 8EM.F

1 Comment

Admin

4 years ago

Editas Medicine, Inc is currently in a long term downtrend where the price is trading 4.0% below its 200 day moving average.

From a valuation standpoint, the stock is 97.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 28.4.

Editas Medicine, Inc's total revenue sank by 7.0% to $11M since the same quarter in the previous year.

Its net income has dropped by 65.5% to $-62M since the same quarter in the previous year.

Finally, its free cash flow fell by 205.4% to $-41M since the same quarter in the previous year.

Based on the above factors, Editas Medicine, Inc gets an overall score of 1/5.

ISIN	US28106W1036
Exchange	F
CurrencyCode	EUR
Sector	Healthcare
Industry	Biotechnology

Market Cap	119M
PE Ratio	None
Target Price	54.77
Beta	2.16
Dividend Yield	None

ABOUT

Editas Medicine, Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

8EM.F · Editas Medicine, Inc

-

Editas Medicine, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Editas Medicine, Inc using a moving average strategy